The Centenary Institute’s Professor Warwick Britton AO has hosted the informal launch of the new NHMRC Centre for Research Excellence in Tuberculosis Control on Both Sides of Our Border (TB-CRE).
In August, the TB-CRE secured $2.5 million in NHMRC funding to operate as an interdisciplinary centre of research excellence over five years.
Held at the Centenary Institute last week, all of the Centre’s Chief and Associate Investigators gathered to plan the future directions of the TB-CRE, ahead of its formal launch at the 2019 TB-CRE Symposium in May.
Diagnostic tests and a vaccine for tuberculosis have been available for more than 100 years, while effective drugs have been available for more than 60 years.
Despite this, tuberculosis remains the world’s deadliest infectious disease.
The TB-CRE is focused on:
You can read more about the TB-CRE on its website.
Our Immune-Vascular Interactions Laboratory’s Dr Elinor Hortle and Dr Stefan Oehlers have found a brand new target for treating drug-resistant tuberculosis.
Research by Centenary’s Dr Stefan Oehlers in collaboration with the University of Sydney has identified a powerful tool to fight tuberculosis.
Cancer Council NSW awards funding to innovative cancer research projects including Centenary’s Professor Phil Hansbro and Dr Justin Wong.